Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Clin Cancer Res. 2019 Aug 1;25(21):6443–6451. doi: 10.1158/1078-0432.CCR-19-0138

Figure 2. Time to Progression with Various Therapies Among Patients with Metastatic HR+/HER2− Breast cancer, Stratified by FGFR1 Amplification.

Figure 2.

1A) Time to Progression (TTP) on first line Endocrine-based Therapy in patients with metastatic HR+/HER2− breast cancer, stratified by FGFR1 amplification status.

1B) TTP on first exposure to Chemotherapy among patients with metastatic HR+/HER2− breast cancer, stratified by FGFR1 amplification status.

1C) TTP on first line Endocrine Therapy in combination with CDK 4/6 inhibitor among patients with metastatic HR+/HER2− breast cancer, stratified by FGFR1 amplification status.

1D) TTP on first exposure to Endocrine Therapy in combination with mTOR inhibitor among patients with metastatic HR+/HER2− breast cancer, stratified by FGFR1 amplification status.